The Role of Angiogenesis-related Pathways in the Development of Port Wine Stains
NCT ID: NCT03948997
Last Updated: 2021-03-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2015-10-01
2019-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. The late-stage cobblestoning appearance of PWS subjects is comprised by not only pronounced vascular ectasia with proliferation of thin and/or thick-walled vessels and their stroma, but also numerous epithelial, neural and mesenchymal hamartomatous abnormalities. Despite these histologic observations, the specific mechanisms involved in PWS nodular formation remains unclear.
3. In one nodular PWS subject, we found that phosphatidylinositol 3-kinases (PI3K)/protein kinase B (AKT) and phosphoinositide phospholipase C g subunit (PLC-g) were activated in both hypertrophic areas and nodules within the lesion. These observations led us to hypothesize that the PI3K pathway may play an important role in nodular formation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
French National Cohort of Children With Port Wine Stain
NCT01364857
Exacerbation of Erythema Following PDT in Patients With Probable Capillary Malformation-Arteriovenous Malformation Syndrome: Retrospective Analysis of Ultrasound and Clinical Characteristics.
NCT06985563
Ontogeny of Infantile Hemangiomas With Skin Imaging Modalities
NCT02061735
Predicting Pediatric Pulmonary Vein Stenosis Outcomes Using Data Acquired During a Cardiac Catheterization
NCT04696289
Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas
NCT00374335
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group
Patients with port wine stains receive PDL (1.5-10ms, 11-12.5J/cm2) with a treatment range of approximately 10\*10cm2
Pulsed dye laser (PDL)
Pulsed dye laser (PDL, 595nm) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis
No treatment group
Patients with port wine stains have not been treated with PDL treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pulsed dye laser (PDL)
Pulsed dye laser (PDL, 595nm) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient and the family of the child agreed to participate in the experiment and signed an informed consent form;
* Clinical diagnosis of refractory port wine stains with thickened nodular or PDL resistance; .There is no bleeding, ulceration, infection, etc. affecting the visual field of laser surgery operation.
Exclusion Criteria
* Heart disease patients;
* Epilepsy patient;
* Pregnant patient;
* Researchers believe that patients who are not suitable for this experiment
1 Month
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Air Force General Hospital of the PLA
OTHER_GOV
First Hospital of China Medical University
OTHER
Chinese Academy of Medical Sciences
OTHER
xjpfW
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
xjpfW
Head of Dermatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gang Wang, Prof
Role: PRINCIPAL_INVESTIGATOR
Dermatology Derpartment of Xijing Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XijingH-PF-20150902
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.